Asston Pharmaceuticals IPO: Full Details, Strategy, and Review

Introduction

Asston Pharmaceuticals Limited, a growing pharmaceutical exporter, is set to launch its BSE SME IPO on July 9, 2025, offering investors a chance to participate in India’s expanding pharma manufacturing and export sector. This IPO will raise fresh capital to scale up production, boost working capital, and reduce debt, aligning with its vision of becoming a prominent global healthcare supplier.

IPO Details

• IPO Type: Book Building

• IPO Open Date: July 9, 2025

• IPO Close Date: July 11, 2025

• Listing Date: Tentatively July 16, 2025

• Stock Exchange: BSE SME

• Price Band: ₹115 to ₹123 per share

• Face Value: ₹10 per share

• Lot Size: 1,000 shares (Minimum 2 lots i.e. 2,000 shares for retail investors)

• Total Issue Size: 22.41 lakh shares (₹27.56 crore)

• Market Maker: JSK Securities and Services Pvt. Ltd.

• Registrar: Maashitla Securities Pvt. Ltd.

• Lead Manager: Sobhagya Capital Options Ltd.

Minimum Investment Requirement

• Retail Investors: Minimum 2 lots (2,000 shares) = ₹2,46,000

• HNI Investors: Minimum 3 lots (3,000 shares) = ₹3,69,000

IPO Reservation Breakup

• Market Maker: 1,13,000 shares (5.04%)

• QIB: 10,60,000 shares (47.30%)

• NII (HNI): 3,22,000 shares (14.37%)

• Retail Individual Investors: 7,46,000 shares (33.29%)

• Anchor Investors: 6,35,000 shares (28.34%), raising ₹7.81 crore on July 8, 2025

Anchor Investors Details

• Anchor Bidding Date: July 8, 2025

• Shares Offered: 6,35,000

• Amount Raised: ₹7.81 crore

• Lock-In Periods:

  • 50% until August 13, 2025 (30 days)

  • Remaining 50% until October 12, 2025 (90 days)

IPO Timeline (Tentative)

Promoter Holding

• Promoters: Dr. Ashish Narayan Sakalkar, Saili Jayaram More, Sachin Chandrakant Badakh

• Pre-Issue Holding: 68.76%

• Post-Issue Holding: 50.66%

Objects of the Issue

The company plans to use the ₹27.56 crore raised for:

1. Funding capital expenditure (machinery acquisition) – ₹6 crore

2. Funding incremental working capital – ₹13 crore

3. Repayment/prepayment of borrowings – ₹1 crore

4. General corporate purposes

About the Company

Asston Pharmaceuticals Limited was incorporated in 2019. The company focuses on manufacturing and exporting pharmaceutical formulations including tablets, capsules, sachets, and syrups across therapeutic categories such as:

• Analgesics: Ibuprofen, Diclofenac

• Antibiotics, Antifungals

• Vitamins and Nutraceuticals

• Albendazole USP 400 mg – broad-spectrum anti-parasitic

• Ferrovit Syrup – vitamins and minerals

Key Strengths

• Formulation Expertise in diverse dosage forms

• Experienced Promoters with pharma industry knowledge

• Diverse Product Portfolio across therapeutic classes

• Strategic Location supporting exports

• Certified Facilities (FDA Central/State, NQA-accredited)

• Skilled Workforce: 46 permanent, 6 contract employees

Company’s Business Model

Asston Pharmaceuticals sells its products:

• Directly under its own brand

• On contract manufacturing and loan license basis

• Following a principle-to-principle approach with marketing partners

Manufacturing Certifications

• Central & State FDA approvals

• NQA (Nuclear Quality Assurance) accreditation

• Quality Management System (QMS) compliance

Company Financials (₹ in Crore)

Growth Highlights

• Revenue up 62% YoY (FY25 vs FY24)

• PAT up 218% YoY

Key Performance Indicators (as of March 31, 2025)

• Market Cap: ₹104.70 crore

• ROE: 50.56%

• ROCE: 51.25%

• Debt/Equity: 0.68

• RoNW: 40.36%

• PAT Margin: 17.27%

• EBITDA Margin: 24.60%

• Price-to-Book: 12.07

• EPS: ₹6.90 (Pre-IPO) / ₹9.32 (Post-IPO)

• P/E Ratio: 17.83 (Pre-IPO) / 13.2 (Post-IPO)

Competitive Advantages

• Growing global demand for Indian generics and formulations

• Asset-light model via contract manufacturing flexibility

• High-margin export opportunities

• Regulatory compliance ensuring market access

Risks to Consider

• Dependence on exports and foreign market regulations

• Raw material price fluctuations

• Competitive pricing pressure

• SME segment volatility post-listing

• High minimum investment (₹2.46 lakh for retail investors)

Investment Outlook

• Who Should Consider:

  • Investors bullish on India’s pharma export story

  • Those seeking SME IPO exposure with moderate-to-high risk appetite

  • Long-term investors betting on manufacturing expansion

• Caution:

  • SME IPOs can be illiquid and volatile.

  • High minimum investment may limit s

Disclaimer:

This article is intended for informational and educational purposes only and does not constitute investment advice. Readers are advised to consult their financial advisor before making any investment decisions. Investments in securities are subject to market risks. Please read all related documents carefully before applying for the IPO. The data provided is based on publicly available information and may be subject to change.

The Upcoming IPOs in this week and coming weeks are  Asston Pharmaceuticals, CFF Fluid Control, Smarten Power Systems, Glen Industries, Travel Food Services, Anthem Biosciences, Chemkart India.

The Current active IPO are Crizac, Meta Infotech, Happy Square Outsourcing Services, Cryogenic OGS.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.

The Asston Pharmaceuticals IPO offers an opportunity to participate in India’s booming pharma export sector through a company that has shown strong financial growth and solid margins. However, investors should carefully evaluate pricing, liquidity, and risk factors typical of the SME segment before investing.